With the rapidly evolving KRAS niche from seemingly intractable therapeutically to a vast array of different MOAs now appearing in company pipelines, you could well be forgiven for thinking of Perry Como singing ‘it’s beginning to look a lot like Christmas.’ 

The sheer number of new agents, novel targets, different MOAs, and even creative combination strategies emerging is making this niche incredibly hard – albeit rewarding – to keep up with.

Every time we post even a mini update there seems to be something new to discuss and the latest review is no different in this respect… prepare to be pleasantly surprised!

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by